India markets close in 6 hours 7 minutes
  • BSE SENSEX

    48,735.85
    +58.30 (+0.12%)
     
  • Nifty 50

    14,649.75
    +31.90 (+0.22%)
     
  • USD/INR

    73.8360
    +0.0260 (+0.04%)
     
  • Dow

    34,230.34
    +97.34 (+0.29%)
     
  • Nasdaq

    13,582.42
    -51.08 (-0.37%)
     
  • BTC-INR

    4,200,030.00
    +153,136.00 (+3.78%)
     
  • CMC Crypto 200

    1,464.67
    +59.36 (+4.22%)
     
  • Hang Seng

    28,442.43
    +24.43 (+0.09%)
     
  • Nikkei

    29,300.30
    +487.70 (+1.69%)
     
  • EUR/INR

    88.6253
    -0.0050 (-0.01%)
     
  • GBP/INR

    102.5765
    -0.0635 (-0.06%)
     
  • AED/INR

    20.0460
    -0.0050 (-0.02%)
     
  • INR/JPY

    1.4781
    +0.0017 (+0.12%)
     
  • SGD/INR

    55.2400
    -0.0320 (-0.06%)
     

Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Appili Therapeutics Inc. (TSX:APLI; OTCQX:APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that the Company’s Chief Executive Officer, Dr. Armand Balboni will present at the fully virtual Bloom Burton & Co. Healthcare Investor Conference taking place on April 20 and 21, 2021.

Appili management will be conducting one-to-one meetings throughout the conference and is scheduled to present as follows:

Date: Wednesday, April 21st
Time: 10:00 AM ET

A live webcast of Appili’s presentation can be accessed on the Company’s website on the Events and Presentations page. A replay of the presentation will also be made available following the live presentation.

To request virtual one-to-one meetings, please register for the conference HERE.

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan® / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

ABOUT BLOOM BURTON & CO

Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).

For more information, visit https://www.bloomburton.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005145/en/

Contacts

Investor Relations Contacts:
Kimberly Stephens, CFO
Appili Therapeutics
TSX: APLI
E: Info@AppiliTherapeutics.com

Laura Kiernan, IRC, CPA
High Touch Investor Relations
T: 914-598-7733
E: AppiliTherapeutics@htir.net